BNGO - Bionano Genomics, Inc.
| Previous Close | 1.0900 |
| Open | 1.0700 |
| Bid | 0.0000 x 1800 |
| Ask | 0.0000 x 34100 |
| Day's Range | 1.0100 - 1.1200 |
| 52 Week Range | 0.5000 - 8.0000 |
| Volume | 3,736,785 |
| Avg. Volume | 5,360,053 |
| Market Cap | 29.668M |
| Beta (3Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -2.6940 |
| Earnings Date | Nov 7, 2019 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 3.00 |
- Benzinga
Benzinga Pro's Top 5 Stocks To Watch For Thurs., Dec. 5, 2019: KR, YETI, BNGO, GOOS, ULTA
Shares traded slightly lower following Q3 earnings of $0.47/share on sales of $27.974 billion. YETI (YETI) - Goldman Sachs upgraded the stock to Buy and set a new $37 price target. Goldman's new price target represented potential upside of 11%.
- GlobeNewswire
Breakthrough Findings in Leukemias Presented at ASH 2019 Demonstrate Bionano Saphyr’s Potential to Replace All Cytogenetic Methods and Show Additional Clinical Utility
Bionano’s new DNA Isolation Kit for Bone Marrow Aspirates enables routine clinical analysis of Leukemia samples. SAN DIEGO, Dec. 05, 2019 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (BNGO), a life sciences instrumentation company that develops and markets the Saphyr® System, a genome imaging platform for ultra-sensitive and ultra-specific genome-wide structural variation detection, today announced four leukemia studies using its technology published in the special edition of the prestigious journal Blood prior to the start of the Annual Meeting of the American Society of Hematology (ASH) being held December 7-10th in Orlando, Florida. Bionano is today also announcing the launch of its DNA isolation kit for Bone Marrow Aspirates (BMA), the primary material collected in leukemia patients.
- Zacks
Bionano Genomics, Inc. (BNGO) Upgraded to Buy: What Does It Mean for the Stock?
Bionano Genomics, Inc. (BNGO) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank 2 (Buy).
- GlobeNewswire
Takeaways from AMP 2019 in Baltimore: Users of Bionano’s Saphyr System Presented Results from Multiple Studies Demonstrating the System’s Utility for a Variety of Disease Indications
A team of clinicians and scientists from the Moffitt Cancer Center and Bionano Genomics, led by Dr. Anthony Magliocco, M.D, of Protean BioDiagnostics, presented a study on HPV-positive ovarian tumors and two pairs of primary ovarian tumors with matched ascites. Ascites is the abnormal build-up of fluid in the abdomen, which can be caused by an inflammatory reaction to metastatic cancer cells.
- GlobeNewswire
Bionano Genomics Reports Third Quarter 2019 Financial Results and Provides Business Update
SAN DIEGO, Nov. 07, 2019 -- Bionano Genomics, Inc. (NASDAQ: BNGO), a life sciences instrumentation company that develops and markets Saphyr®, a platform for ultra-sensitive and.
- Benzinga
The Daily Biotech Pulse: Obseva Sinks On Adverse Clinical Readout, BioNano Surges On Saphyr Adoption, 2 IPOs
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Nov. 6) Agile Therapeutics Inc (NASDAQ: AGRX )(follow-on rally ...
- GlobeNewswire
Novogene Adopts Bionano’s Saphyr System Adding Saphyr’s Ultra-Sensitive and Ultra-Specific Structural Variation Detection to their Repertoire of Services
Bionano Genomics, Inc. (BNGO) announced today that Novogene has adopted the Saphyr system for genome imaging and incorporated it into their expansive repertoire of genome analysis technology services. Novogene is one of the premier genome analysis technology providers in the world.
- GlobeNewswire
Bionano Genomics to Report Third Quarter 2019 Financial Results and Host a Conference Call and Webcast on November 7
SAN DIEGO, Nov. 04, 2019 -- Bionano Genomics, Inc. (NASDAQ: BNGO), a life sciences instrumentation company that develops and markets Saphyr, a platform for ultra-sensitive and.
- GlobeNewswire
Takeaways from ASHG 2019 in Houston: Users of Bionano’s Saphyr System Presented Validation Results for FSHD, Repeat Expansion Disorders and Digital Cytogenetics Among a Growing List of Applications of Saphyr in Human Genetics and Cancer Research
At ASHG and at the satellite education event held prior to the conference and organized by Bionano, clinicians and researchers using the Saphyr system to analyze samples from patients with genetic diseases and cancer presented a series of new findings and validation results that support the adoption of Saphyr as a complement to next-generation sequencing for variant discovery and as a replacement for traditional cytogenetic methods in variant detection for clinical applications. Alka Chaubey, Ph.D., Head of Cytogenomics at PerkinElmer Genomics summarized the validation of Saphyr technology by PerkinElmer that enabled the development of PerkinElmer’s assay for Facioscapulohumeral Dystrophy (FSHD), which PerkinElmer and the University of Iowa developed based on the Bionano EnFocus™ FSHD Analysis tool.
- GlobeNewswire
Bionano Genomics Announces Pricing of $18 Million Underwritten Public Offering
BIONANO GENOMICS, INC. (BNGO), a life sciences instrumentation company that develops and markets Saphyr, a platform for ultra-sensitive and ultra-specific structural variation detection in genome analysis, today announced the pricing of an underwritten public offering of 20,937,558 shares of its common stock (or pre-funded warrants to purchase common stock in lieu thereof) and common warrants to purchase up to an aggregate of 20,937,558 shares of common stock. Each share of common stock and, as applicable, pre-funded warrant is being sold together with a common warrant to purchase one share of common stock at a combined effective price to the public of $0.86 per share and accompanying common warrant. For each pre-funded warrant Bionano sells, the number of shares of common stock Bionano is offering will be decreased on a one-for-one basis.
- GlobeNewswire
Bionano Genomics Announces Adoption of Its Saphyr® System by Clinical Cytogenetics Groups in Academia and Industry to Replace Traditional Methods for Clinical Testing
Bionano Genomics, Inc. (BNGO), a life sciences instrumentation company that develops and markets the Saphyr® system, a genome imaging platform for ultra-sensitive and ultra-specific genome-wide structural variation detection, today announced that leading organizations, including PerkinElmer Genomics and the University of Iowa, have adopted Saphyr for use in their clinical genomics laboratories. PerkinElmer Genomics and the University of Iowa have developed assays based on the Bionano optical mapping technology to expand their comprehensive suite of genetic tests assessing disease-associated chromosomal abnormalities.
- GlobeNewswire
Top Researchers to Present Discoveries Made Possible by Bionano’s Saphyr System for Genome Imaging Technology at the ASHG 2019 Annual Meeting
SAN DIEGO, Oct. 16, 2019 -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced that disease researchers using Bionano’s Saphyr system for whole genome imaging will present.
- Simply Wall St.
What Kind Of Shareholder Owns Most Bionano Genomics, Inc. (NASDAQ:BNGO) Stock?
A look at the shareholders of Bionano Genomics, Inc. (NASDAQ:BNGO) can tell us which group is most powerful. Large...
- GlobeNewswire
Bionano Genomics to Present at the H.C. Wainwright 21st Annual Global Investment Conference
SAN DIEGO, Sept. 09, 2019 -- Bionano Genomics, Inc. (NASDAQ: BNGO), a life sciences instrumentation company that develops and markets Saphyr®, a platform for ultra-sensitive.
- GlobeNewswire
Bionano Genomics Releases Users’ Video Presentations of Preliminary Data Affirming Saphyr's Potential to Replace Traditional Cytogenetics Methods in Certain Blood Cancers
Bionano Genomics, Inc. (BNGO), a life sciences instrumentation company that develops and markets Saphyr®, a platform for ultra-sensitive and ultra-specific structural variation detection in genome analysis, today announced the release on its website of video presentations of results from two key studies presented this month at the 2019 Cancer Genomics Consortium (CGC) Annual Meeting. The video presentations are available for viewing at www.bionanogenomics.com/library/videos. A preliminary read-out by Professor Brynn Levy, Director of Cytogenetics at Columbia University, regarding 11 patient samples analyzed and unblinded from a multi-center clinical validation study. This study compares Saphyr to technologies used in traditional cytogenetics workflows for patient testing in oncology and is being run by a consortium of leading cytogenetics teams at institutions in the United States, including Columbia University, MD Anderson Cancer Center, Mayo Clinic, University of Washington, Penn State University, Augusta University and PathGroup.
- GlobeNewswire
Preliminary Data Confirm Saphyr’s Potential to Replace Traditional Cytogenetics Methods for Detection of Structural Variants in Certain Blood Cancers
In a preliminary read-out of a multi-center clinical validation study using blinded samples, Professor Brynn Levy, Director of Cytogenetics at Columbia University, presented outcomes on the first 11 patient samples analyzed and unblinded. This study compares Saphyr to technologies used in traditional cytogenetics workflows for patient testing in oncology and is being run by a consortium of leading cytogenetics teams at institutions in the United States, including Columbia University, the MD Anderson Cancer Center of the University of Texas, the Mayo Clinic, the University of Washington, Penn State University, Augusta University and the PathGroup. In each of the 11 samples, Saphyr detected all known clinical variants identified by various combinations of karyotype, Fluorescent In-Situ Hybridization (FISH), and Chromosomal MicroArray (CMA), which define the current standard of care in cytogenetics.
- GlobeNewswire
Bionano Genomics Reports Second Quarter 2019 Financial Results and Provides Business Update
SAN DIEGO, Aug. 08, 2019 -- Bionano Genomics, Inc. (NASDAQ: BNGO), a life sciences instrumentation company that develops and markets Saphyr®, a platform for ultra-sensitive and.
- GlobeNewswire
Bionano Genomics to Report Second Quarter 2019 Financial Results and Host a Conference Call and Webcast on August 8
SAN DIEGO, Aug. 02, 2019 -- Bionano Genomics, Inc. (NASDAQ: BNGO), a life sciences instrumentation company that develops and markets Saphyr®, a platform for ultra-sensitive and.
- Simply Wall St.
How Much Are Bionano Genomics, Inc. (NASDAQ:BNGO) Insiders Spending On Buying Shares?
It is not uncommon to see companies perform well in the years after insiders buy shares. The flip side of that is that...
- GlobeNewswire
Results Presented at ESHG 2019 Showcase the Advantages of Saphyr over Traditional Cytogenetics Methods for the Detection of Structural Variants in Patients with Genetic Disease and Cancer
On Monday, June 17th, researchers will highlight results in oral presentations and poster presentations of studies comparing Bionano optical mapping to technologies used in traditional cytogenetics workflows used for patient testing in genetic diseases and oncology. In a poster from the team of Dr. Alex Hoischen at Radboud University Medical Center in the Netherlands entitled, “Next generation cytogenetics in medical genetics with high-resolution optical mapping,” Tuomo Mantere and colleagues describe the comparison of Bionano optical mapping on Saphyr with a suite of traditional cytogenetic methods – fluorescence in situ hybridization (FISH), karyotyping and chromosomal microarray (CMA).
- GlobeNewswire
Clinical Researchers Present Initial Results from Key Clinical Studies Designed to Evaluate the Performance of Saphyr® Against Traditional Cytogenetics Methods at the European Human Genetics Conference
In a workshop on June 16, speakers from leading clinical research hospitals in Europe who are evaluating Bionano optical mapping with the Saphyr system against traditional cytogenetics workflows, will present initial results that demonstrate Saphyr’s ability to modernize existing workflows. Dr. Alexander Hoischen, PhD, from Radboud University Medical Center in the Netherlands, will provide an update on their study comparing Bionano optical mapping with Saphyr to the current clinical testing workflows for Chronic Myelogenous Leukemia (CML) and Acute Lymphoblastic Leukemia (ALL) among other hematologic malignancies and some genetic disorders.
- GlobeNewswire
Leading Scientists and Clinicians Are Presenting Results From a Record Number of Studies at ESHG 2019 Showing How the Saphyr System From Bionano Genomics Provides Critical Insights Into Cancer and Genetic Disease and is Leading the Way to Digital Cytogenetics
SAN DIEGO, June 13, 2019 -- Bionano Genomics, Inc. (NASDAQ: BNGO), a life sciences instrumentation company that develops and markets Saphyr®, a platform for ultra-sensitive and.
- GlobeNewswire
Bionano Genomics Appoints Kristiina Vuori, MD, PhD, to its Board of Directors
SAN DIEGO, June 12, 2019 -- Bionano Genomics, Inc. (NASDAQ: BNGO), a life sciences instrumentation company that develops and markets Saphyr®, a platform for ultra-sensitive and.
- GlobeNewswire
Bionano Genomics Reports First Quarter 2019 Financial Results and Provides Business Update
SAN DIEGO, May 09, 2019 -- Bionano Genomics, Inc. (NASDAQ: BNGO), a life sciences instrumentation company that develops and markets Saphyr®, a platform for ultra-sensitive and.
- GlobeNewswire
Bionano Genomics to Report First Quarter 2019 Financial Results and Host a Conference Call and Webcast on May 9
SAN DIEGO, May 03, 2019 -- Bionano Genomics, Inc. (NASDAQ: BNGO), a life sciences instrumentation company that develops and markets Saphyr, a platform for ultra-sensitive and.
